Comprehensive review of potential drugs with anti-pulmonary fibrosis properties - 22/03/24
Abstract |
Pulmonary fibrosis is a chronic and progressive lung disease characterized by the accumulation of scar tissue in the lungs, which leads to impaired lung function and reduced quality of life. The prognosis for idiopathic pulmonary fibrosis (IPF), which is the most common form of pulmonary fibrosis, is generally poor. The median survival for patients with IPF is estimated to be around 3–5 years from the time of diagnosis. Currently, there are two approved drugs (Pirfenidone and Nintedanib) for the treatment of IPF. However, Pirfenidone and Nintedanib are not able to reverse or cure pulmonary fibrosis. There is a need for new pharmacological interventions that can slow or halt disease progression and cure pulmonary fibrosis. This review aims to provide an updated overview of current and future drug interventions for idiopathic pulmonary fibrosis, and to summarize possible targets of potential anti-pulmonary fibrosis drugs, providing theoretical support for further clinical combination therapy or the development of new drugs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Idiopathic pulmonary fibrosis remains a challenging disease with no effective cure. |
• | New drugs and treatment strategies are urgently needed to improve the quality of life for patients with pulmonary fibrosis. |
• | This systematic review evaluates the antifibrotic potential of non-antifibrotic agents and investigational drugs. |
Keywords : Pulmonary fibrosis, Lung injury, Potential drug, Drug target, New therapies
Plan
Vol 173
Article 116282- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?